These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 39038425)
1. The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer. Bar Y; Bar K; Feldman D; Dror JB; Shahoha M; Lerner S; Shachar SS; Weiss-Meilik A; Dershowitz N; Wolf I; Sonnenblick A Breast; 2024 Oct; 77():103777. PubMed ID: 39038425 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. Zeng Y; Gao W; Chen X; Shen K Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279 [TBL] [Abstract][Full Text] [Related]
3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318 [TBL] [Abstract][Full Text] [Related]
4. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast]. Yang M; Xu SP; Ao QL Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534 [TBL] [Abstract][Full Text] [Related]
5. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567 [TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression. Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637 [TBL] [Abstract][Full Text] [Related]
7. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729 [TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins. Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190 [TBL] [Abstract][Full Text] [Related]
9. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214 [TBL] [Abstract][Full Text] [Related]
10. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611 [TBL] [Abstract][Full Text] [Related]
11. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
12. Genetic predisposition to ductal carcinoma in situ of the breast. Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359 [TBL] [Abstract][Full Text] [Related]
13. Overall survival is improved when DCIS accompanies invasive breast cancer. Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308 [TBL] [Abstract][Full Text] [Related]
14. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943 [TBL] [Abstract][Full Text] [Related]
15. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer. Cedolini C; Bertozzi S; Londero AP; Seriau L; Andretta M; Agakiza D; Fongione S; Uzzau A; Risaliti A Int J Clin Exp Pathol; 2015; 8(10):13304-13. PubMed ID: 26722534 [TBL] [Abstract][Full Text] [Related]
16. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189 [TBL] [Abstract][Full Text] [Related]
17. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Park K; Han S; Kim HJ; Kim J; Shin E Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686 [TBL] [Abstract][Full Text] [Related]
18. Clinical implications of growth pattern and extension of tumor-associated intraductal carcinoma of the breast. Eggemann H; Kalinski T; Ruhland AK; Ignatov T; Costa SD; Ignatov A Clin Breast Cancer; 2015 Jun; 15(3):227-33. PubMed ID: 25516401 [TBL] [Abstract][Full Text] [Related]
19. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component. Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370 [TBL] [Abstract][Full Text] [Related]
20. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]